Related by context. All words. (Click for frequent words.) 83 evaluable patients 81 evaluable 75 evaluable subjects 74 partial remissions 73 RECIST criteria 72 CR CRu 72 complete cytogenetic 72 HBeAg positive patients 70 cytogenetic response 70 chlorambucil 70 Partial Responses 69 dosing cohorts 69 complete remissions 69 achieved CCyR 69 HBeAg negative patients 69 remission CR 69 cytogenetic responses 69 MCyR 68 undetectable HBV DNA 68 achieved sustained virological 68 placebo dexamethasone 68 achieved PASI 68 CR nPR 68 REYATAZ r arm 68 mg kg dose 68 CRp 68 RECIST 67 comparator arm 67 KRAS mutations occur 67 CCyR 67 receiving VICTRELIS 67 dose cohort 67 achieved ACR# 67 heavily pretreated patients 67 achieved sustained virologic 67 relapsed MM 67 mcg albinterferon alfa 2b 67 APTIVUS r 67 underwent resection 66 splenectomized patients 66 Fludara 66 prospectively defined 66 dose cohorts 66 mg ustekinumab 66 RGT arm 66 underwent surgical resection 66 tumor shrinkage 66 FOLPI 66 biochemical relapse 66 Doxil ® 66 FOLFOX4 66 CIMZIA TM 66 mg/m2 dose 66 Folfox 66 Secondary endpoints 66 Response Evaluation Criteria 66 Kaplan Meier estimate 66 8mg/kg 66 mg QD 65 RECIST Response Evaluation Criteria 65 pegylated interferon alfa 2b 65 heavily pretreated 65 follicular lymphomas 65 mg BID 65 % CI #.#-#.# [003] 65 FOLFOX 65 free survival PFS 65 FluCAM arm 65 recurrent glioblastoma multiforme 65 complete cytogenetic response 65 galiximab 65 Flu Cy 65 TMC# r 65 #mg BID [001] 65 prior chemotherapy regimens 65 squamous histology 65 certolizumab 65 oblimersen 65 plus dexamethasone 65 PASI scores 65 tumor regression 65 HUMIRA achieved PASI 65 endoscopic remission 65 ALT flares 65 atazanavir ritonavir 65 desvenlafaxine succinate 65 Partial Response 65 PRECiSE 65 systemic ALCL 65 postoperative chemotherapy 64 locoregional recurrence 64 ACR Pedi 64 chemoradiotherapy 64 lung metastases 64 melphalan prednisone 64 microgram kg 64 Secondary endpoints include 64 chemoradiation 64 recurrent GBM 64 GOUT 64 lymphocytosis 64 Aptivus ® 64 dose escalation phase 64 mcg doses 64 receiving golimumab 64 carboplatin paclitaxel 64 pegylated interferon alpha 64 metastatic GIST 64 iniparib BSI 64 Secondary endpoints included 64 mcg QD 64 CIMZIA ™ 64 distant metastasis 64 methotrexate monotherapy 64 DLTs 64 mcg kg 64 lopinavir r arm 64 eosinophilic asthma 64 dosing cohort 64 locoregional 64 #mg dose [002] 64 low dose cytarabine 64 treatment naive genotype 64 ACTEMRA TM 63 mg kg cohorts 63 CANCIDAS 63 haematologic 63 adalimumab 63 pegylated liposomal doxorubicin 63 Solid Tumors criteria 63 timepoints 63 mCRC patients 63 dasatinib 63 VFEND 63 secondary efficacy endpoints 63 HCV RESPOND 2 63 ribavirin RBV 63 adjunctive placebo 63 FOLFIRINOX 63 nodular partial response 63 mycophenolate mofetil 63 amoxicillin clavulanate 63 achieving PASI 63 events SAEs 63 oral rivaroxaban 63 peginterferon 63 hA# 63 platinum refractory 63 octreotide LAR 63 Kaplan Meier analysis 63 ara C 63 plus methotrexate 63 Hycamtin ® 63 Rate ORR 63 TEAEs 63 FOLFIRI 63 preoperative chemotherapy 63 q#d 63 #mg BID [003] 63 TELCYTA 63 estramustine 63 imatinib 63 #mg QD [002] 63 bendamustine 63 virologic breakthrough 63 CLL SLL 63 dose limiting toxicities 63 Solid Tumors RECIST 63 placebo controlled clinical trials 63 Peg IFN 63 crizotinib PF # 63 nab paclitaxel 63 PegIFN RBV 63 mcg dose 63 mg/m2/day 63 telaprevir dosed 63 #mg/m# [002] 63 YERVOY 63 receiving INTRON 63 GVAX 63 gefitinib 63 Free Survival PFS 63 progression TTP 63 mcg BID 63 remission induction 63 4mg/kg 62 CHOP chemotherapy 62 LEXIVA r 62 PEG IFN 62 plus gemcitabine 62 neurologic progression 62 HCV SPRINT 62 adjuvant tamoxifen 62 unresectable stage 62 azacitidine 62 posaconazole 62 doripenem 62 μg doses 62 FOLFOX6 62 μg dose 62 ZACTIMA 62 metastatic renal cell 62 median PFS 62 decitabine 62 DAS# CRP 62 papillary renal cell carcinoma 62 FOLFOX4 alone 62 Engerix B 62 locoregional disease 62 ACTEMRA 62 Median survival 62 KRAS status 62 postintervention 62 febrile neutropenia 62 mRCC 62 Pegasys plus Copegus 62 lymphopenia 62 HBeAg positive 62 metastatic RCC 62 standard chemotherapy regimen 62 cisplatin chemotherapy 62 timepoint 62 CAMMS# 62 Bezielle 62 micafungin 62 Complete Response CR 62 pomalidomide 62 HBeAg seroconversion 62 log# reduction 62 rituximab 62 Amrubicin 62 oral diclofenac 62 tumor progression TTP 62 CIMZIA TM certolizumab pegol 62 GLIADEL R Wafer 62 pCR 62 mg BID dose 62 hepatitis C genotype 62 tapentadol ER 62 elotuzumab 62 oxycodone CR 62 tolerability profiles 62 STELARA 62 Follicular Lymphoma 62 peginterferon alfa 2a 62 treatment naïve genotype 62 clodronate 62 histologically confirmed 62 % CI #.#-#.# [007] 62 #mg/m# [001] 62 infliximab 62 piperacillin tazobactam 62 5-FU/LV 62 bortezomib refractory 62 vandetanib 62 TORISEL 62 Randomized Phase 62 alfa 2a 62 Primary endpoints 62 INC# 62 BRIM2 62 biliary tract cancer 62 neoadjuvant treatment 62 CRu 62 ACR# response 61 EBMT criteria 61 PREZISTA rtv 61 nadolol 61 response CCyR 61 NATRECOR R 61 neoadjuvant 61 virologic failure 61 rFVIIa 61 MGd 61 metastatic CRC 61 Pharmacokinetics PK 61 CMV disease 61 underwent CABG 61 alemtuzumab treated 61 docetaxel chemotherapy 61 mapatumumab 61 IIIB NSCLC 61 PREZISTA r 61 teriflunomide 61 neoadjuvant chemotherapy 61 relapsed MCL 61 tumor regressions 61 HBeAg 61 seroprotection 61 IFN α 61 multicenter Phase 61 leukemia AML 61 cabazitaxel 61 prospectively stratified 61 viral kinetics 61 peginterferon alfa 2a #KD 61 mesalamine granules 61 EURIDIS 61 Colorectal Cancer Patients 61 ascending dose 61 etanercept 61 ertapenem 61 BARACLUDE ® 61 Virologic 61 cinacalcet 61 dacarbazine DTIC 61 darunavir ritonavir 61 composite endpoint 61 NovoTTF 61 fluvastatin 61 androgen suppression 61 hematologic 61 clinically meaningful improvement 61 FLT3 ITD 61 Taxotere ® 61 peg IFN 61 receiving highly emetogenic 61 mCi kg 61 DMARD 61 R# #mg BID 61 sorafenib Nexavar ® 61 tipranavir ritonavir 61 lenalidomide Revlimid R 61 HSCT 61 ARB telmisartan 61 oral FTY# 61 pertuzumab 61 virological response 61 recurrent GBM patients 61 liver metastases 61 SVR# 61 discontinuations due 61 NMIBC 61 solifenacin 61 huC# DM4 61 nondiabetic patients 61 Xelox 61 splenectomized 61 rindopepimut 61 liver transplant recipients 61 CYPHER Stent 61 advanced adenoma 61 sustained virological response 61 hematologic toxicity 61 glufosfamide 61 virological failure 61 Dacogen injection 61 acneform rash 61 stage IIIb 61 ALT normalization 61 colorectal carcinomas 61 definite stent thrombosis 61 advanced hepatocellular carcinoma 61 SinuNase TM 61 oral allopurinol 61 paliperidone ER 61 QTc prolongation 61 ascending doses 61 dacarbazine chemotherapy 61 alicaforsen enema 61 azathioprine monotherapy 61 PREZISTA r arm 61 undetectable HCV RNA 61 MabThera Rituxan 61 sustained virologic response 61 Pegylated Interferon 61 stage IIIb IV 61 huN# DM1 61 HGS ETR1 60 LPV r 60 EDSS scores 60 biologic DMARD 60 median survivals 60 prior relapsers 60 metastatic renal cell carcinoma 60 mg qd 60 Index CDAI 60 adalimumab Humira 60 hypophosphatemia 60 Median progression 60 Renal Cell Carcinoma RCC 60 DAPT 60 KRAS mutant tumors 60 Efficacy Results 60 genotypic resistance 60 mcg kg REBETOL 60 elevated ALT 60 chemoradiation therapy 60 receiving PEGINTRON 60 APTIVUS 60 eplerenone 60 severe neutropenia 60 measurable tumor regressions 60 resected pancreatic cancer 60 imatinib therapy 60 Hepatocellular Carcinoma HCC 60 neoadjuvant therapy 60 nilotinib 60 % Confidence Interval 60 morphometric vertebral fractures 60 NNRTI resistance 60 aminotransferase elevations greater 60 subcutaneous PRO 60 Tarceva erlotinib 60 refractory NSCLC 60 HER2 positive metastatic breast 60 low dose dexamethasone 60 phase IIb study 60 undergone splenectomy 60 satraplatin Phase 60 visceral metastases 60 tumor lysis syndrome 60 â ‰ ¥ 60 mg dose 60 rapid virologic response 60 severe oral mucositis 60 ritonavir boosted 60 IMGN# 60 cEVR 60 stage IIIB 60 mg administered orally 60 DOXIL 60 corticosteroid therapy 60 ORENCIA ® 60 Peginterferon 60 rosuvastatin #mg 60 prucalopride 60 TLUS 60 T#I mutation 60 evaluating tivozanib 60 azacytidine 60 concurrent chemoradiation 60 docetaxel Taxotere 60 rituximab refractory 60 ribavirin therapy 60 Elitek 60 angiographic outcomes 60 dose dexamethasone 60 intermittent dosing 60 oral Hycamtin 60 DEB# 60 thrombocytopenic 60 RECORD1 60 adverse cytogenetics 60 mutated KRAS 60 genotype 1a 60 postdose 60 irinotecan chemotherapy 60 doxorubicin cyclophosphamide 60 interferon alfa 60 ENDEAVOR II 60 temsirolimus 60 posttreatment 60 cancer mCRC 60 interferon ribavirin 60 TAXOTERE R 60 HCV infected 60 antibody MAb 60 oral levofloxacin 60 imipenem 60 null responders 60 TIMP 1 60 peg interferon 60 peginterferon alfa 2b 60 unresectable HCC 60 OPT CHF 60 placebo controlled Phase 60 dose escalation 60 metastatic lung cancer 60 infusional 5-FU/LV 60 Traficet EN 60 vaccinees 60 Median PFS 60 refractory metastatic 60 F FDG PET 60 ELACYT 60 events AEs 60 severe exacerbations 60 pharmacodynamic PD 60 MoxDuo TM IR 60 baminercept 60 invasive aspergillosis 60 ispinesib administered 60 TAXUS ATLAS 60 hypercalcemia 60 5-fluorouracil/leucovorin 60 mg/m2 IV 60 liposomal doxorubicin 60 pegylated interferon alfa 2a 60 FOLFIRI alone 60 ponatinib 60 MAGE A3 ASCI 60 fatigue asthenia 60 randomized Phase 2b 60 metastatic pancreatic 60 demonstrated antitumor activity 60 gemcitabine cisplatin 60 nutlin 3a 60 KRAS wild 60 alteplase 60 MACCE 60 Xanafide 60 MYCAMINE 60 tipranavir r 60 docetaxel prednisone 60 Newly Diagnosed Multiple Myeloma 59 histologically proven 59 aprepitant 59 RRMS patients 59 gemcitabine carboplatin 59 mg m² 59 Crohn Disease Activity 59 pharmacokinetics PK 59 mg RDEA# 59 divalproex sodium 59 LibiGel Phase III 59 virologic 59 CTAP# Capsules 59 Pegasys peginterferon alfa 2a 59 microbiological eradication 59 dosage regimens 59 Zyclara 59 nonvertebral fractures 59 tumor necrosis 59 univariate analysis 59 adjuvant cisplatin 59 microgram doses 59 pT2 59 seroconversion 59 SPIRIVA HandiHaler 59 lumiliximab 59 viral kinetic 59 BEACOPP 59 ATACAND 59 mucosal healing 59 forodesine 59 velafermin 59 plus OBT 59 hours postdose 59 AEGR 59 romiplostim 59 transaminase elevations 59 seliciclib 59 mg TID 59 achieve sustained virologic 59 paclitaxel cisplatin 59 Antiviral Activity 59 Pegasys ® 59 mcg linaclotide 59 indolent NHL 59 idraparinux 59 distant metastases 59 trabectedin 59 NSABP B 59 EXJADE 59 Metastatic Colorectal Cancer 59 REMICADE ® 59 ARCOXIA 59 corticosteroid dose 59 mcg Albuferon 59 advanced adenomas 59 relapsed myeloma 59 histological subtype 59 CAELYX 59 Jevtana 59 virologic responses 59 Naive Patients 59 NEUPOGEN 59 HBeAg negative 59 Pemetrexed 59 nadroparin 59 lopinavir r 59 Hepatotoxicity 59 tumor recurrence 59 oral olanzapine 59 null responder HCV 59 BEXXAR 59 refractory CLL 59 mg kg BID 59 n = 59 MabCampath 59 refractory chronic myeloid 59 abiraterone acetate 59 Immunogenicity 59 VaD 59 highly emetogenic 59 ritonavir boosted atazanavir 59 gefitinib Iressa 59 dacarbazine 59 serologically active patients 59 hemostatic efficacy 59 bortezomib 59 Zometa hazard 59 Hodgkin lymphoma HL 59 Solid Tumors 59 moderately emetogenic 59 BENICAR HCT 59 sUA 59 IFN alfa 59 Phase Ib clinical 59 monotherapy 59 ug dose 59 pegylated interferon alfa 59 ABC/3TC 59 recurrent metastatic 59 p = NS 59 laboratory abnormalities 59 recurrent VTE 59 patients receiving ERBITUX 59 insulin detemir 59 seroconverted 59 pancreatic adenocarcinoma 59 TroVax ® 59 cisplatin gemcitabine 59 Tumor shrinkage 59 dasatinib Sprycel ® 59 statin monotherapy 59 odanacatib 59 pT3 59 salmeterol fluticasone 59 Cimzia ® certolizumab pegol 59 #mg dosing group 59 cytoreduction 59 Alocrest 59 refractory AML 59 relapsed AML 59 entecavir 59 goserelin 59 abacavir lamivudine 59 ErbB2 positive 59 antiangiogenic therapy 59 antibody titers 59 achieved statistical significance 59 caspofungin 59 multicenter randomized controlled 59 #mg/day [001] 59 Pivotal Phase III 59 dosing intervals 59 fluorouracil 59 Scale EDSS 59 #mg q8h 59 DMARDS 59 Tarceva TM 59 relapsed refractory multiple myeloma 59 bolus dose 59 bosutinib 59 dexamethasone Decadron 59 posttransplant 59 active comparator 59 fluorouracil leucovorin 59 Camptosar ® 59 monoinfected patients 59 low dose Iluvien 59 treatment emergent adverse 59 SUTENT 59 antiretroviral naïve 59 HCV genotypes 59 fluoropyrimidine 59 3mg/kg 59 azathioprine 59 SCIg 59 dose melphalan 59 secondary efficacy endpoint 59 adjunctive ABILIFY 59 doxorubicin docetaxel 59 NOXAFIL 59 clinically meaningful improvements 59 generalized edema 59 colorectal liver metastases 59 serum HCV RNA 59 response pCR 59 zalutumumab 58 COPD exacerbation 58 tacrolimus ointment 58 daunorubicin 58 macroalbuminuria 58 refractory CML 58 neratinib 58 adefovir treated 58 sirolimus eluting stent 58 paricalcitol 58 cisplatin vinorelbine 58 bosentan 58 AZT zidovudine Retrovir 58 hematologic adverse 58 Aflibercept 58 sorafenib Nexavar 58 ixabepilone 58 nitazoxanide 58 peginterferon alpha 2a 58 chemo radiotherapy 58 abatacept 58 topotecan 58 Phase Ib II 58 retrospective cohort 58 FluCAM 58 serum antibody 58 K ras mutations 58 clinically meaningful differences 58 Telintra 58 briakinumab 58 adjuvant radiotherapy 58 ACR# responses 58 intravenous bisphosphonates 58 AVOREN 58 trastuzumab Herceptin R 58 iniparib 58 Fludarabine 58 XIENCE V PROMUS Stent 58 chronic GVHD 58 rFSH 58 canakinumab 58 nonfatal MI 58 EOquin TM 58 heFH 58 Velcade bortezomib 58 underwent liver transplantation 58 Ozarelix 58 infliximab monotherapy 58 REYATAZ R 58 sunitinib malate 58 Pivotal Phase 58 calcineurin inhibitor 58 mitoxantrone 58 DAS# remission 58 Decitabine 58 metastatic HRPC 58 hepatorenal syndrome 58 plasma uric acid 58 operable breast cancer 58 zonisamide SR 58 hepatic metastases 58 enzastaurin 58 hepatocellular carcinomas 58 ipsilateral breast 58 cilengitide 58 REMICADE monotherapy 58 anakinra 58 mITT population 58 Interferon alfa 58 discontinuations 58 anaplastic astrocytomas 58 FFNS 58 MADRS score 58 anthracycline taxane 58 APPRAISE 58 Patients Receiving 58 epithelial tumors 58 LUX Lung 58 nonmetastatic prostate cancer 58 sunitinib 58 PREZISTA ritonavir 58 elacytarabine 58 acute HAE attacks 58 gout flares 58 Ceplene/IL-2 58 ZYVOX 58 hormone receptor negative 58 Natalizumab 58 Kaplan Meier estimates 58 placebo controlled clinical 58 nucleotide analog 58 recurrent NSCLC 58 Events MACE 58 ELOXATIN 58 BENCHMRK 58 GnRH agonist 58 plus ribavirin 58 multicenter Phase III 58 nonresponders 58 VICTRELIS 58 antibody titer 58 mg/m2 58 pamidronate 58 basal cell carcinoma BCC 58 neutropenia dehydration dyspnea 58 TNF antagonists 58 REVIVE TA 58 peripheral sensory neuropathy 58 non metastatic osteosarcoma 58 Phase 1b 58 microgram dose 58 vidofludimus 58 recurrent genital herpes 58 Raptiva r 58 Stage IIIb 58 radioiodine therapy 58 mg q8h 58 mitoxantrone plus 58 receptor tyrosine kinase inhibitor 58 secondary endpoint 58 Retreatment 58 tolvaptan 58 T1c 58 ug kg 58 anastrazole 58 allogeneic stem cell 58 seropositive patients 58 Triapine R 58 serum cortisol 58 Platinol ® 58 vinorelbine 58 MVax R 58 lumbar spine BMD 58 XELOX 58 dose cytarabine 58 oral clodronate 58 BEXXAR Therapeutic Regimen 58 VcMP 58 multicenter placebo controlled 58 progressive PsA 58 ketoconazole 58 metastatic kidney 58 placebo controlled studies 58 differentiated thyroid 58 HIV HCV coinfected 58 pancreatic carcinoma 58 T#I [002] 58 Hazard Ratio 58 Pooled Analysis 58 interferon alfa 2b 58 Non Responders 58 aflibercept 58 intracranial hemorrhage ICH 58 ischemic cardiomyopathy 58 lamivudine refractory patients 58 RSD# oral 58 Secondary efficacy endpoints 58 HCV genotype 58 5 Fluorouracil 58 infliximab therapy 58 experienced virologic failure 58 fallopian tube cancers 58 AA Amyloidosis 58 refractory gout 58 virologic response 58 RE SURGE 58 Sym# 58 vicriviroc 58 tigecycline 58 APTIVUS R 58 Adalimumab 58 EFAPROXYN 58 S. aureus isolates 58 completely resected 58 hour bronchodilation 58 renal cell carcinomas 58 COPEGUS 58 Chronic Lymphocytic Leukemia CLL 58 Randomized Phase II 58 adjuvant GIST 58 Cimzia TM 58 NATRECOR ® 58 prespecified 58 sipuleucel T 58 boosted protease inhibitor 58 GetGoal Phase III 58 pimecrolimus cream 58 breast carcinoma 58 IV NSCLC 58 moderate renal impairment 58 zoledronic acid 58 GnRH agonists 58 histologies 58 antithymocyte globulin 58 lamivudine monotherapy 58 rizatriptan 58 Ophena TM 58 relapsers 58 Toxicities 58 relapsed refractory 58 IMC A# 58 rotigotine 58 intravenous bolus 58 raltegravir 58 motesanib 58 secondary endpoints 58 methotrexate MTX 58 serum urate 58 mg q#h 58 EGFR mutation positive 58 ongoing Phase 1b 58 BRIM3 58 nonrandomized 58 mg/m2 administered 58 infliximab Remicade 58 TNF antagonist 58 follicular lymphoma FL 58 COPAXONE R 58 GRASPA ® 58 HIV uninfected 58 vertebral fracture 58 dose regimens 58 resectable 58 trials RCTs 58 RAPTIVA 57 TNF inhibitors 57 STN stimulation 57 intra articular injection 57 RE LY ® 57 SPRYCEL ® 57 debulking surgery 57 administered subcutaneously 57 SCH # 57 conjunctival hyperemia 57 Eloxatin R 57 NSCLC 57 xenograft models 57 tanespimycin 57 Q#IR 57 sirolimus stent 57 tamoxifen therapy 57 Irinotecan 57 metastatic malignant 57 mg eq 57 Raptiva ® 57 keloid scarring 57 intravesical 57 erlotinib Tarceva ® 57 lymphoid malignancies 57 BCIRG 57 Allovectin 7 ® 57 pitavastatin 57 interferon IFN 57 levetiracetam 57 protease inhibitor PI 57 mg/# hr 57 ruboxistaurin 57 INTELENCE 57 vismodegib 57 HER2 overexpression 57 histologic subtype 57 thalidomide Thalomid 57 Ph + ALL 57 aged ≥ 57 zoledronate 57 budesonide foam 57 afatinib 57 Copegus ribavirin 57 -#.# log# copies mL 57 EGFR TKI 57 assessing T DM1 57 ANCHOR trial 57 steroid dexamethasone 57 nucleoside naive 57 Tolerability 57 anti leukemic 57 eribulin mesylate 57 gemcitabine chemotherapy 57 TDF FTC 57 ritonavir boosted lopinavir 57 4CMenB 57 chronic HCV genotype 57 tumor xenograft models 57 EDSS score 57 methotrexate therapy 57 μg kg 57 pharmacokinetic PK study 57 non splenectomized 57 preintervention 57 adefovir 57 Gemzar ® 57 HGPIN 57 fludarabine 57 QTcF 57 PSMA ADC 57 #Gy 57 Soft Tissue Sarcoma 57 ipsilateral stroke 57 baseline PASI 57 nonmetastatic 57 seronegative 57 anthracycline containing 57 subtrochanteric 57 randomized #:# 57 rilonacept 57 pegylated interferon peg IFN 57 trastuzumab Herceptin ® 57 anemia hemoglobin 57 titration phase 57 peginterferon alfa 57 VAPRISOL 57 phase Ib 57 atazanavir sulfate 57 tocilizumab 57 daily subcutaneous injections 57 docetaxel Taxotere ® 57 zolmitriptan 57 PSADT 57 docetaxel 57 anthracyclines taxanes 57 cutaneous squamous cell carcinoma 57 ibandronate 57 underwent radical prostatectomy 57 esophageal carcinoma 57 CLARITY study 57 otamixaban 57 maximally tolerated dose 57 BR.#